This is a preview of subscription content, log in via an institution to check access.
References
Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33–47.
Hauben M, Aronson J, Ferner R. Evidence of misclassification of drug-event associations classified as gold-standard ‘negative controls’ by the Observational Medical Outcomes Partnership (OMOP). Drug Saf. 2016. doi:10.1007/s40264-016-0392-2.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to assist in the preparation of this commentary.
Conflict of interest
Jim Slattery has no conflicts of interest that are directly relevant to the content of this commentary.
Additional information
The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.
Rights and permissions
About this article
Cite this article
Slattery, J. Measuring Signal Detection Performance: Can We Trust Negative Controls and Do We Need Them?. Drug Saf 39, 371–373 (2016). https://doi.org/10.1007/s40264-016-0407-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-016-0407-z